Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenatumomab I 131 - sigma-tau SpA

Next Previous
Search
Drug Profile

Tenatumomab I 131 - sigma-tau SpA

Alternative Names: 131I-Tenatumomab; 131Iodine-Tenatumomab; I131 anti-Tenascin monoclonal antibody; Tenatumomab/ST2146

Latest Information Update: 28 Dec 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sigma-tau SpA
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunomodulators; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Dec 2018 No recent reports of development identified for phase-I development in Cancer(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in France (IV, Infusion)
  • 28 Dec 2018 No recent reports of development identified for phase-I development in Cancer(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in Italy (IV, Infusion)
  • 11 Jan 2018 sigma-tau SpA terminates a phase I trial as the uptake of drug into the tumour lesion was negligible in Cancer (In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in France and Italy (IV) (NCT02602067)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top